journal
MENU ▼
Read by QxMD icon Read
search

American Health & Drug Benefits

journal
https://read.qxmd.com/read/30746019/a-proposed-intervention-to-decrease-resident-performed-cataract-surgery-cancellation-in-a-tertiary-eye-care-center
#1
Eileen L Mayro, Laura T Pizzi, Lisa A Hark, Ann P Murchison, Douglas Wisner, Anish Koka, Benjamin E Leiby, Nooreen Dabbish, Adedoyin Okulate, Alexa Dessy, Caitlin Green, Robert Bailey
Background: Cataracts are the leading cause of preventable blindness globally. As a result, competence in cataract surgery is an important component of ophthalmology residency training. Residency programs must optimize the number of cataract surgery cases to train proficient physicians. However, the rate of cataract surgery cancellations is high, and some are canceled because of preventable causes. Objective: To evaluate the effect of mandatory on-site preadmission testing, including having a physical examination, on resident-performed cataract surgery cancellation rates...
December 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30746018/pharmacist-led-drug-therapy-problem-management-in-an-interprofessional-geriatric-care-continuum-a-subset-of-the-pivots-group
#2
Ashley M Campbell, Kim C Coley, Jason M Corbo, Teresa M DeLellis, Matthew Joseph, Carolyn T Thorpe, Melissa S McGivney, Patricia Klatt, Lora Cox-Vance, Vincent Balestrino, Heather Sakely
Background: Drug therapy problems, which are adverse events involving medications that can ultimately interfere with a patient's therapeutic goals, occur frequently in older adults. If not identified, resolved, and prevented through clinical decision-making, drug therapy problems may negatively affect patient health outcomes. Objective: To quantify the impact of pharmacist interventions on the care of older adults by identifying the most common drug therapy problems, the medications most often involved in these problems, and the actions taken by pharmacists to resolve these problems...
December 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30746017/potential-cost-savings-with-once-daily-aminomethylcycline-antibiotic-versus-vancomycin-in-hospitalized-patients-with-acute-bacterial-skin-and-skin-structure-infections
#3
Ken LaPensee, Thomas Lodise
Background: Omadacycline is an oral and intravenous (IV) once-daily aminomethylcycline antibiotic that was recently approved by the US Food and Drug Administration for the treatment of patients with acute bacterial skin and skin structure infections (ABSSSI). In 2 phase 3 clinical trials, IV-to-oral switch and oral-only administration of omadacycline achieved the primary end points of noninferiority compared with linezolid in treating patients with ABSSSI. Objective: To estimate the potential cost-savings with bioequivalent IV-to-oral antibiotics, such as omadacycline, compared with the standard of care with IV vancomycin by avoiding hospitalizations and reducing hospital stays in patients presenting from the emergency department for ABSSSI treatment...
December 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30687455/shut-off-the-faucet-and-stop-mopping-the-floor
#4
EDITORIAL
David B Nash
No abstract text is available yet for this article.
December 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647830/treatment-tolerability-in-patients-with-immunoglobulin-light-chain-amyloidosis
#5
Avery A Rizio, Michelle K White, Kristen L McCausland, Tiffany P Quock, Spencer D Guthrie, Miyo Yokota, Martha S Bayliss
Background: Immunoglobulin light-chain amyloidosis (AL amyloidosis) is a rare and often fatal disease for which there is currently no treatment approved by the US Food and Drug Administration or the European Medicines Agency. Treatment options, which are typically based on therapies for multiple myeloma and are used off-label, are associated with substantial adverse events (AEs). Because the severity of AEs is often determined by clinicians, evaluations of treatment tolerability may not fully consider patients' own experience with treatment...
November 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647829/fda-commissioner-outlines-new-plan-to-increase-biosimilars-by-balancing-innovation-and-competition
#6
Eileen Koutnik-Fotopoulos
No abstract text is available yet for this article.
November 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647828/patient-preferences-associated-with-therapies-for-psoriatic-arthritis-a-conjoint-analysis
#7
Yihua Xu, Lavanya Sudharshan, Ming-Ann Hsu, Andrew S Koenig, Joseph C Cappelleri, Wen F Liu, Timothy W Smith, Margaret K Pasquale
Background: As psoriatic arthritis (PsA) treatment choices continue to expand, it is important to consider patient preferences for treatment modalities for PsA. Involving patients in treatment decisions can influence adherence to treatment and outcomes of therapy. Objective: To determine patient preferences for medication attributes prescribed for patients with PsA. Methods: A choice-based conjoint survey was mailed to 2800 randomly selected patients with PsA who were enrolled in Humana Medicare and commercial plans...
November 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647827/healthcare-costs-and-absenteeism-among-caregivers-of-adults-with-partial-onset-seizures-analysis-of-claims-from-an-employer-database
#8
Richard A Brook, Krithika Rajagopalan, James E Smeeding
Background: Partial-onset seizures are the most common type of seizures in patients with epilepsy. In addition to the significant impact on patients, the unpredictability of seizures often also affects family members or caregivers. Caregiver burden in relation to patient treatment may help to guide treatment choices for patients. Quantitative evidence about the relationship between workplace absences, costs, and treatment burden among caregivers of patients with partial-onset seizures is lacking...
November 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647826/unscaling-population-health
#9
EDITORIAL
David B Nash
No abstract text is available yet for this article.
November 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647825/budget-impact-analysis-of-using-daunorubicin-cytarabine-liposome-in-patients-with-newly-diagnosed-therapy-related-aml-or-aml-and-myelodysplasia-related-changes
#10
Ivar S Jensen, Elizabeth Wu, Naomi C Sacks, Philip L Cyr, Karen C Chung
Background: Current national estimates for acute myelogenous leukemia (AML) indicate this disease accounts for 1.1% of new cancer diagnoses and 1.8% of cancer deaths in the United States. The 5-year overall survival rate for patients with AML was 27.4% between 2008 and 2014. The standard induction for patients with AML includes cytarabine, infused for 7 days, with 3 once-daily injections of an anthracycline, such as daunorubicin, known as the 7+3 regimen. Daunorubicin plus cytarabine liposomal encapsulation for injection was approved in the United States in 2017 for adults with newly diagnosed therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC)...
October 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647824/alternative-payment-models-in-medical-oncology-assessing-quality-of-care-outcomes-under-partial-capitation
#11
Derek Ems, Sharanya Murty, Bryan Loy, Judith Gallagher, Laura E Happe, Teresa L Rogstad, Debra Finnel, Jimmy D Fernandez
Background: Alternative payment models (APMs) in healthcare are emerging that reward quality of care over quantity of services. Most bundled payment programs that are described in published studies are related to episodes for a surgical inpatient hospital stay. With outpatient services, monthly capitated payments are an alternative to bundled payments for specialty services. Objective: To assess the association of a capitated contractual arrangement between a primary care physician group and an oncology clinic group with the quality of care received...
October 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647823/computed-tomography-colonography-less-costly-than-colonoscopy-for-colorectal-cancer-screening-of-commercially-insured-patients
#12
Tia Goss Sawhney, Bruce S Pyenson, David Rotter, Michele Berrios, Judy Yee
Background: Computed tomography (CT) colonography's effectiveness, its associated patient advantages, and its potential role to increase colorectal cancer (CRC) screening rates have been demonstrated in previous research, but whether CT colonography has a cost advantage relative to optical colonoscopy for the commercially insured US population has not been assessed. Objective: To compare the costs of CRC screening using CT colonography or optical colonoscopy for commercially insured people in the United States...
October 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647822/economic-burden-of-adverse-events-associated-with-immunotherapy-and-targeted-therapy-for-metastatic-melanoma-in-the-elderly
#13
Sameer R Ghate, Zhiyi Li, Jackson Tang, Antonio Reis Nakasato
Background: Immunotherapies and targeted therapies have drastically improved survival in metastatic melanoma, but they can cause a range of adverse events (AEs). Understanding the costs of these events would facilitate an accurate comparison of melanoma treatments. Objective: To compare the costs and frequency of AEs associated with immunotherapy and with targeted therapy in elderly patients with metastatic melanoma. Methods: We conducted a retrospective cohort study using Medicare claims data from 2011 to 2014...
October 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30647821/-hoodoo-you-think-will-change
#14
EDITORIAL
David B Nash
No abstract text is available yet for this article.
October 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30464797/estimating-the-real-world-cost-of-diabetes-mellitus-in-the-united-states-during-an-8-year-period-using-2-cost-methodologies
#15
Vincent J Willey, Sheldon Kong, Bingcao Wu, Amit Raval, Todd Hobbs, Andrea Windsheimer, Gaurav Deshpande, Ozgur Tunceli, Brian Sakurada, Jonathan R Bouchard
Background: Diabetes is associated with substantial clinical and economic burdens on patients and on the US healthcare system. Treatment options for patients with type 1 or type 2 diabetes have increased significantly, from only 3 drug classes in 1995 to more than 12 distinct classes today. Although several of the newer treatments are reported to have improved efficacy and safety profiles, they are often substantially more costly than older medications. Consequently, as drug options increase, the cost of diabetes management continues to grow...
September 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30464796/analysis-of-real-world-dosing-patterns-for-the-3-fda-approved-medications-in-the-treatment-of-fibromyalgia
#16
Craig White, Winghan Jacqueline Kwong, Hilary Armstrong, Michael Behling, Jeffrey Niemira, Kathy Lang
Background: Fibromyalgia is a chronic condition characterized by widespread pain, fatigue, and sleep disturbances that affects approximately 2% to 4% of the adult population in the United States, with minimal real-world data related to the use of medications and associated dosages for this condition. Objective: To analyze the real-world dosing patterns of the 3 medications approved by the US Food and Drug Administration for fibromyalgia-pregabalin, duloxetine, and milnacipran...
September 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30464795/trends-in-utilization-spending-and-prices-of-smoking-cessation-medications-in-medicaid-programs-25-years-empirical-data-analysis-1991-2015
#17
Xiaomeng Yue, Jeff Jianfei Guo, Patricia R Wigle
Background: Smoking remains the single largest preventable cause of death and disease. Smoking-cessation medications provide patients a multitude of benefits and can prevent certain diseases, including some cancers. Because of the limited amount of studies on smoking-cessation medications, we wanted to find general trends about the use of these medications. Objective: To examine trends in the utilization, pharmacy reimbursement, and prices of smoking-cessation medications and nicotine replacement therapy in the US Medicaid-covered population...
September 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30464794/-the-dirty-dozen
#18
EDITORIAL
David B Nash
No abstract text is available yet for this article.
September 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30464793/budget-impact-of-adding-vedolizumab-to-a-health-plan-formulary-as-another-first-line-biologic-option-for-ulcerative-colitis-and-crohn-s-disease
#19
Michele Wilson, Aaron Lucas, Ann Cameron, Michelle Luo
Background: Vedolizumab is a biologic drug approved by the US Food and Drug Administration (FDA) for the treatment of adults with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) who have had inadequate response to, lost response to, or were intolerant of immunomodulators or tumor necrosis factor (TNF) blocker therapy, or who had an inadequate response with, were intolerant to, or demonstrated dependence on corticosteroid therapy. The biologics approved by the FDA for CD and/or UC include adalimumab, infliximab, golimumab, certolizumab, and ustekinumab...
July 2018: American Health & Drug Benefits
https://read.qxmd.com/read/30464792/the-prevalence-and-payer-costs-of-potentially-avoidable-emergent-care-visits-for-suspected-amniotic-membrane-rupture-in-pregnant-women
#20
Christine Ferro, Bruce S Pyenson, Jocelyn Lau, Mona Kelkar, Nancy Phillips, Chi-Wei Lu, Percy Yeung, Gloria Bachmann
Background: Concern over amniotic fluid leakage is common among pregnant women. Uncertainty about prelabor rupture of amniotic membranes (PROM) can lead women to present to emergency departments or to labor and delivery units for medical evaluation. Many of such visits do not result in delivery, yet they carry significant, and potentially unnecessary, healthcare expenditures. Objective: To estimate the prevalence and payer cost of potentially avoidable visits by pregnant women to an emergent care facility (including emergency departments, labor and delivery units, or observation units) for suspected PROM...
July 2018: American Health & Drug Benefits
journal
journal
48448
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"